Logo

Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases

Share this
Biocytogen

Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases

Shots:

  • Biocytogen has signed an antibody evaluation and option agreement with Gilead Sciences for the development of various novel antibody-based therapies to treat multiple disease
  • The collaboration grants Gilead, access to Biocytogen’s fully human antibody library to select the targets of interest over a 3yr. nomination period and investigate them with an option to own the selected antibodies for development across the globe
  • Biocytogen will obtain payment for helping Gilead in investigating antibodies for nominated target, option exercise fees, milestones for achieving development, regulatory & sales for each selected antibody against the nominated targets along with single-digit net sales-based royalties

Ref: Biocytogen| Image: Biocytogen

Related News:- Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions